"With approximately 72 million Americans classified as obese and a disease prevalence that has increased by more than 75 percent since 1980, obesity is one of the most pressing public health issues facing the United States today. Harmful side effect profiles and moderate weight-loss benefits have plagued the obesity treatment landscape, but with Alli's entry into the over-the-counter market, the success of bariatric surgical procedures and innovative medications in development, the future of obesity treatment is bound to keep consumers, doctors and investors on their toes. This panel will explore therapeutic targets for obesity focused on the central nervous system, with drugs targeting neurotransmitters and those designed to limit absorption of fat in the gut as well as the latest in bariatric medicine."

Objective 1: Review the current landscape of obesity treatments and surgeries.

Objective 2: Discuss the benefits of new obesity therapies on the market.

Objective 3: Explore reasons why obesity is much bigger than a lifestyle issue.